BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 27149447)

  • 21. Systematic review and meta-analysis of candidate gene association studies of benign prostate hyperplasia.
    Lin L; Li P; Liu X; Xie X; Liu L; Singh AK; Singh HN
    Syst Rev; 2022 Apr; 11(1):60. PubMed ID: 35382870
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BPH: a tell-tale sign of prostate cancer? Results from the Prostate Cancer and Environment Study (PROtEuS).
    Boehm K; Valdivieso R; Meskawi M; Larcher A; Sun M; Sosa J; Blanc-Lapierre A; Weiss D; Graefen M; Saad F; Parent MÉ; Karakiewicz PI
    World J Urol; 2015 Dec; 33(12):2063-9. PubMed ID: 25824539
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Body size throughout the life-course and incident benign prostatic hyperplasia-related outcomes and nocturia.
    Khan S; Wolin KY; Pakpahan R; Grubb RL; Colditz GA; Ragard L; Mabie J; Breyer BN; Andriole GL; Sutcliffe S
    BMC Urol; 2021 Mar; 21(1):47. PubMed ID: 33773592
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Smoking habits and benign prostatic hyperplasia: A systematic review and meta-analysis of observational studies.
    Xu H; Fu S; Chen Y; Chen Q; Gu M; Wang Z
    Medicine (Baltimore); 2016 Aug; 95(32):e4565. PubMed ID: 27512883
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diabetes mellitus and risk of prostate cancer: an updated meta-analysis based on 12 case-control and 25 cohort studies.
    Zhang F; Yang Y; Skrip L; Hu D; Wang Y; Wong C; Qiu J; Lei H
    Acta Diabetol; 2012 Dec; 49 Suppl 1():S235-46. PubMed ID: 23124624
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Male pattern baldness and incidence of prostate cancer: A systematic review and meta-analysis.
    He H; Xie B; Xie L
    Medicine (Baltimore); 2018 Jul; 97(28):e11379. PubMed ID: 29995779
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alcohol and the risk of prostate cancer and benign prostatic hyperplasia.
    Crispo A; Talamini R; Gallus S; Negri E; Gallo A; Bosetti C; La Vecchia C; Dal Maso L; Montella M
    Urology; 2004 Oct; 64(4):717-22. PubMed ID: 15491708
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hyperthyroidism is not a significant risk of benign prostatic hyperplasia: A nationwide population-based study.
    Man KM; Chen KB; Chen HY; Chiang JH; Su YC; Man SS; Xie DD; Wang Y; Zhang ZQ; Bi LK; Zhang T; Yu DX; Chen WC
    Medicine (Baltimore); 2018 Sep; 97(39):e12459. PubMed ID: 30278528
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic association between PSA-158G/A polymorphism and the susceptibility of benign prostatic hyperplasia: a meta-analysis.
    Su XJ; Zeng XT; Fang C; Liu TZ; Wang XH
    Oncotarget; 2017 May; 8(20):33953-33960. PubMed ID: 28430620
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antihypertensive medications are associated with the risk of kidney and bladder cancer: a systematic review and meta-analysis.
    Xie Y; Xu P; Wang M; Zheng Y; Tian T; Yang S; Deng Y; Wu Y; Zhai Z; Hao Q; Song D; Zhang D; Dai Z
    Aging (Albany NY); 2020 Jan; 12(2):1545-1562. PubMed ID: 31968309
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 5α-Reductase Inhibitors and Risk of Kidney and Bladder Cancers in Men with Benign Prostatic Hyperplasia: A Population-Based Cohort Study.
    Doherty N; Cardwell CR; Murchie P; Hill C; Azoulay L; Hicks B
    Cancer Epidemiol Biomarkers Prev; 2023 Mar; 32(3):428-434. PubMed ID: 36634196
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Correlation of androgen receptor CAG repeats with the risks of benign prostatic hyperplasia and prostate cancer: a meta-analysis].
    Wang XM; Sun L; Zhang Z; Shi XH; Zhang YG; Wei D; Wan B; Yang Z; Wang JY
    Zhonghua Nan Ke Xue; 2014 Feb; 20(2):172-6. PubMed ID: 24520673
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sexually transmitted infections, benign prostatic hyperplasia and lower urinary tract symptom-related outcomes: results from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
    Breyer BN; Huang WY; Rabkin CS; Alderete JF; Pakpahan R; Beason TS; Kenfield SA; Mabie J; Ragard L; Wolin KY; Grubb RL; Andriole GL; Sutcliffe S
    BJU Int; 2016 Jan; 117(1):145-54. PubMed ID: 25601300
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of a hexanic extract of Serenoa repens (Permixon
    Vela-Navarrete R; Alcaraz A; Rodríguez-Antolín A; Miñana López B; Fernández-Gómez JM; Angulo JC; Castro Díaz D; Romero-Otero J; Brenes FJ; Carballido J; Molero García JM; Fernández-Pro Ledesma A; Cózar Olmos JM; Manasanch Dalmau J; Subirana Cachinero I; Herdman M; Ficarra V
    BJU Int; 2018 Dec; 122(6):1049-1065. PubMed ID: 29694707
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia.
    Pattanaik S; Mavuduru RS; Panda A; Mathew JL; Agarwal MM; Hwang EC; Lyon JA; Singh SK; Mandal AK
    BJU Int; 2019 Jul; 124(1):27-34. PubMed ID: 30681264
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Ultrasound indicators of the prostate, urinary bladder and uroflowmetry parameters in the diagnosis of infravesical obstruction in men with benign prostatic hyperplasia].
    Krivoborodov GG; Efremov NS; Bolotov AD
    Urologiia; 2017 Oct; (5):9-14. PubMed ID: 29135135
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Statin use and risk of prostate cancer: a meta-analysis of observational studies.
    Bansal D; Undela K; D'Cruz S; Schifano F
    PLoS One; 2012; 7(10):e46691. PubMed ID: 23049713
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serenoa repens for benign prostatic hyperplasia.
    Wilt T; Ishani A; Mac Donald R
    Cochrane Database Syst Rev; 2002; (3):CD001423. PubMed ID: 12137626
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increased risk of prostate cancer and benign prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect.
    Habuchi T; Liqing Z; Suzuki T; Sasaki R; Tsuchiya N; Tachiki H; Shimoda N; Satoh S; Sato K; Kakehi Y; Kamoto T; Ogawa O; Kato T
    Cancer Res; 2000 Oct; 60(20):5710-3. PubMed ID: 11059764
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer.
    Kunath F; Grobe HR; Rücker G; Motschall E; Antes G; Dahm P; Wullich B; Meerpohl JJ
    Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD009266. PubMed ID: 24979481
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.